Rose, Angela M. C.Pozo, FranciscoMartínez‐Baz, IvánMazagatos, ClaraBossuyt, NathalieCauchi, John PaulPetrović, GorankaLoghin, Isabela I.Vaikutyte, RobertaBuda, SilkeMachado, AusendaDuffy, RóisínOroszi, BeatrixHoward, JenniferEcheverria, AitziberAndreu, CristinaBarbezange, CyrilDžiugytė, AušraNonković, DianaPopescu, Corneliu‐PetruMajauskaite, FaustaTolksdorf, KristinGómez, VerónicaDomegan, LisaHorváth, Judit KrisztinaCastilla, JesúsGarcía, MiriamDemuyser, ThomasBorg, Maria‐LouiseTabain, IrenaLazar, MihaelaKubiliute, IevaDürrwald, RalfGuiomar, RaquelO'Donnell, JoanKristóf, KatalinNicolay, NathalieBacci, SabrinaKissling, EstherVEBIS SARI VE network teamBelgium SARI Surveillance Network (BelsariNet)2025-01-302025-01-302024-02-25Influenza Other Respir Viruses. 2024 Feb;18(2):e13255. doi: 10.1111/irv.132551750-2640http://hdl.handle.net/10400.18/10326We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39) against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.engSARI PatientsHospitalInfluenzaTest-negative DesignVaccine EffectivenessCuidados de SaúdeVacina GripeEfetividadeVEBIS-LOT1Europejournal article10.1111/irv.1325538403302